Diagnostic TPP for surveillance of lymphatic filariasis

Lymphatic filariasis (LF) is a mosquito-borne parasitic infection that is endemic in 72 countries. Adult worms live in the host lymphatic system for years causing lymphatic dysfunction.

Epidemiology

LF is caused by parasitic worms; *Wuchereria bancrofti*, *Brugia malayi*, or *Brugia timori*. *W. bancrofti* is found in nearly all LF endemic countries and *Brugia* spp are found only in limited areas of a few countries across South-east Asia. The adult worms cause lymphangiectasia, leading to swelling of legs (lymphoedema), scrotum (hydrocele) and other parts of the body. LF is a major cause of disability and is responsible for at least 1.3 million Disability Adjusted Life Years (DALYs) each year (IHME, 2017), resulting in productivity loss at the individual and national level.

Public Health Response

WHA 50.29 called for the elimination of LF as a public health problem. An estimated 51.4 million people were infected with LF as of 2018 (Cromwell E, 2020), a significant reduction since WHO launched the Global Programme to Eliminate Lymphatic Filariasis (GPELF). GPELF aims to interrupt transmission and prevent new disease through the WHO recommended strategy of mass drug administration (MDA). All but 3 of the 72 endemic countries have established national LF elimination programmes and implemented MDA (WHO, 2018). Currently, 23 of 72 endemic countries have reduced infection levels below target thresholds and no longer require MDA nationally. WHO has acknowledged 17 of these 23 countries for meeting the criteria for achieving elimination of LF as a public health problem.

As more national programmes see success and begin to stop MDA, the importance of monitoring for resurgence through surveillance activities increases. As defined in the new NTD Road Map, all LF endemic countries should be implementing post-MDA or post-validation surveillance by 2030 (WPRO., 2017).

Available Diagnostic Tools

WHO recommends repeating the transmission assessment survey (TAS) twice in 2 to 3-year intervals after MDA has stopped. Successful results in both surveys i.e. passing TAS, indicates incident infection remains below target thresholds over all endemic geographical areas and meets the epidemiological criteria for elimination as a public health problem. While the TAS is useful for stop-MDA decisions, it is not powered to measure reductions in prevalence or incidence over time or to be a sensitive measure of recrudescence in transmission potential.

This limitation of the TAS for surveillance is compounded by limitations of the available diagnostics. WHO recommends the Alere Filariasis Test Strip (FTS) for all areas endemic for *W. bancrofti* and *Brugia Rapid Test* for all areas endemic for *Brugia* spp. The FTS which measures circulating filarial antigen (CFA) is used in all steps of the GPELF strategy. However, CFA takes 12 months or more to appear after infection and persists several years after adult worms can no longer reproduce or have died. New diagnostics targeting analytes which represent recent exposure are needed to inform LF post-MDA and post-elimination surveillance and response activities.

Other diagnostic tools available for LF have been reviewed and include antibody-based ELISA formats and antibody-based point of care rapid diagnostic tests specific to *W. bancrofti* and *Brugia* spp. WHO has not recommended these diagnostic tests because the tests have not met required performance characteristics.
The WHO Department of Control of Neglected Tropical Diseases (NTD) manages a diverse portfolio of twenty diseases, each with its own unique epidemiological and diagnostic challenges. It was decided by the Strategic and Technical Advisory Group (STAG), the principal advisory group to WHO for the control of NTDs, that a single WHO working group would help ensure that a unified approach could be used to identify and prioritize diagnostic needs, and to inform WHO strategies and guidance on the subject.

The first meeting of the Diagnostic Technical Advisory Group (DTAG), an advisory group to Department of Control of Neglected Tropical Diseases, was held in Geneva, Switzerland, on 30 and 31 October 2019. DTAG members discussed priorities for the year ahead as well as how to manage the complexity of supporting the diagnostics agenda across the entirety of the WHO NTD portfolio (WHO, 2020). One of the recommendations was that there should be a diagnostic disease specific group to support the Global Programme to Eliminate Lymphatic filariasis noting the diagnostic gaps in settings co-endemic with loiasis, areas implementing triple-therapy MDA and areas under post-treatment or post-elimination surveillance (WHO, 2020).

An LF sub-group of technical experts, end users and other stakeholders was formed and met 29th April 2020 virtually. The sub-group identified the need for improved diagnostics for surveillance, a need previously highlighted by WPRO during its meeting on NTD post-elimination surveillance in the Western Pacific. The need for feasible diagnostic formats and new biomarkers was reiterated by WHO expert panel members during a WHO expert consultation to establish the post-2020 targets for GPELF (WPRO, 2017).

Purpose of the TPP

The purpose of this TPP is to communicate the minimum and ideal characteristics desired to meet the need for discriminating low levels of risk for transmission, i.e. targeted prevalence thresholds in the surveyed areas. An in vitro point-of-care test is needed for the detection of analyte specific to Wuchereria bancrofti, Brugia malayi, and Brugia timori to aid in the surveillance of defined geographic areas as to whether infection and/or transmission potential has increased (recrudescence) or decreased (elimination of transmission).

Bibliography


